Mastodon

Eucalimin (Solution) Instructions for Use

ATC Code

R02AA20 (Other antiseptics)

Active Substance

Eucalypti folium (DAB German Pharmacopoeia)

Clinical-Pharmacological Group

Herbal preparation with antimicrobial and anti-inflammatory action

Pharmacotherapeutic Group

Antiseptic

Pharmacological Action

Herbal remedy. Aqueous and alcoholic extracts from eucalyptus leaves exhibit bactericidal, antiviral, fungicidal, antiprotozoal, and anti-inflammatory effects. The degree of their severity depends on the content of essential oil (0.3-4.5%).

The activity of the main component of the essential oil, cineole (65-85%), is potentiated by pinenes, myrtenol, and tannins (up to 6%). When taken orally and in inhalations, eucalyptus preparations cause expectorant, mucolytic, and bronchodilator effects, and when applied to the skin, an astringent, anti-exudative, antipruritic, anesthetic, and, in higher concentrations, locally irritating effect.

The infusion of eucalyptus leaves, due to the essential oil and a small amount of bitters, increases the secretion of the digestive glands and improves digestion. When used in the form of a tincture, a sedative effect is manifested, due to the aldehyde of isovaleric acid.

Chlorophyllipt, containing a mixture of chlorophylls from eucalyptus leaves, has antimicrobial, especially antistaphylococcal, activity and stimulates regeneration processes. Components of the essential oil, together with organic acids, tannins, and trace elements manganese, zinc, and selenium, increase tissue resistance to hypoxia of various origins.

Indications

As part of combination therapy for acute and chronic infectious and inflammatory diseases of various localization: rhinitis, stomatitis, gingivitis, laryngitis, bronchitis, pneumonia, hyposecretory gastritis, enterocolitis, dysbiosis, cholecystitis, pyelonephritis, vaginitis, colpitis, cervical erosion, burns, dermatitis, radiculitis, neuritis, myositis, trophic ulcers, neurosis, mild form of insomnia, osteochondrosis.

ICD codes

ICD-10 code Indication
F48.0 Neurasthenia
F51.0 Nonorganic insomnia
J00 Acute nasopharyngitis (common cold)
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J31.0 Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis)
J31.2 Chronic pharyngitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
K05 Gingivitis and periodontal diseases
K12 Stomatitis and related lesions
K29 Gastritis and duodenitis
K52.9 Noninfective gastroenteritis and colitis, unspecified
K63.8 Other specified diseases of intestine
K81.0 Acute cholecystitis
K81.1 Chronic cholecystitis
L30.9 Dermatitis, unspecified
L98.4 Chronic skin ulcer, not elsewhere classified
M42 Spinal osteochondrosis
M54.1 Radiculopathy
M54.3 Sciatica
M54.4 Lumbago with sciatica
M60 Myositis
M79.2 Neuralgia and neuritis, unspecified
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N76 Other inflammatory diseases of vagina and vulva
N86 Erosion and ectropion of cervix
T30 Burns and corrosions of unspecified body region
ICD-11 code Indication
6A8Z Affective disorders, unspecified
7A00 Chronic insomnia
7A01 Acute insomnia
7A0Z Insomnia disorders, unspecified
8B93.Z Radiculopathy, unspecified
8E4A.1 Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system
CA00 Acute nasopharyngitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA09.0 Chronic rhinitis
CA09.2 Chronic pharyngitis
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
DA01.Z Diseases of the oral mucosa, unspecified
DA0B.Z Gingival diseases, unspecified
DA0C.Z Periodontal diseases, unspecified
DA0Z Diseases or disorders of the orofacial complex, unspecified
DA42.Z Gastritis, unspecified
DA51.Z Duodenitis, unspecified
DA7Z Diseases of stomach or duodenum, unspecified
DA90.0 Syndromic diarrhea
DA92.1 Pneumatosis intestinalis of the small intestine
DA98.Z Polyps of small intestine, unspecified
DB31.1 Pneumatosis of the colon
DB36.Z Certain infections of the colon, unspecified
DC12.0Z Acute cholecystitis, unspecified
DC12.1 Chronic cholecystitis
DE2Z Diseases of the digestive system, unspecified
EA40 Tropical phagedenic ulcer
EA85.2Z Hand dermatitis, unspecified
EA85.3 Foot dermatitis
EA89 Generalized eczematous dermatitis of unspecified type
EA8Z Dermatitis or eczema, unspecified
EF60 Ischemic ulceration of the skin
EM0Z Unspecified skin disorder
FA85.Z Defects of vertebral end-plates, unspecified
FB30 Infectious myositis
FB32 Other specified disorders of muscle
FB3Z Disorder of muscle, unspecified
FB56 Specified soft tissue diseases, not elsewhere classified
FB56.0 Granuloma of soft tissue due to foreign body, not elsewhere classified
GA00 Vulvitis
GA02.Z Unspecified vaginitis
GA0Z Inflammatory diseases of female genital tract, unspecified
GA15.1 Erosion or ectropion of cervix
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
ME60.2 Ulcerative skin lesion of unspecified nature
ME84.20 Lumbago with sciatica
ME84.3 Sciatica
NE11 Burn of unspecified body region

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer the solution orally, externally, topically, by inhalation, or by intracavitary administration based on the specific clinical indication.

For oral administration, dilute 10-20 drops in 50-100 ml of water; take this dose three to four times daily.

For gargling or mouthwash, use 10-15 drops diluted in one glass of warm water; perform this procedure three to four times per day.

For inhalation therapy, add 10-15 drops to 150-200 ml of hot water; inhale the vapors for 5-10 minutes, repeating one to three times daily.

For topical application on skin or mucous membranes, apply the solution in diluted form; concentration and frequency depend on the severity of the condition.

For intracavitary use (e.g., vaginal douches, bladder irrigation), use a dilution as medically directed; the regimen is determined individually.

Adjust the dose, frequency, and treatment duration individually according to the indication, patient age, and clinical response.

Before initiating a full course, conduct a sensitivity test by administering a single test dose and observing for allergic reactions for 6-8 hours.

Adverse Reactions

Possible allergic reactions to components of the essential oil and chlorophyllipt; when taken orally in high doses – nausea, vomiting, diarrhea, muscle spasms; with frequent and/or prolonged inhalation use – dryness of the mucous membranes of the respiratory tract.

Contraindications

Hypersensitivity to components of the essential oil and chlorophyllipt; atrophy of the mucous membranes of the upper respiratory tract.

Use in Pregnancy and Lactation

The use of eucalyptus leaf preparations containing ethyl alcohol is contraindicated during pregnancy and breastfeeding.

Pediatric Use

The use of eucalyptus leaf preparations containing ethyl alcohol is contraindicated in children and adolescents under 18 years of age.

Special Precautions

Use with caution in case of increased secretion of the digestive glands.

Avoid contact of eucalyptus preparations (especially tincture, eucalyptus oil, chlorophyllipt) with the eyes.

Before starting treatment, it is necessary to check the patient’s sensitivity to the plant. For this, the patient is given a tablespoon of infusion, 10 drops of tincture, or 25 drops of a 1% alcohol solution of chlorophyllipt in 1 tablespoon of water. If no allergic reactions occur within 6-8 hours, a course of treatment can be prescribed. A negative attitude of the patient to the smell of eucalyptus may indicate intolerance.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Pharmtsentr Vilar JSC (Russia)

Dosage Form

Bottle OTC Icon Eucalimin Solution for topical application and inhalations 0.25%: bottle 25 ml or 50 ml

Dosage Form, Packaging, and Composition

Solution for topical application and inhalations 0.25% 1 L
Eucalimin (sum of phenolic compounds of Eucalyptus viminalis) 2.5 g

Excipients : ethanol.

25 ml – dark glass bottles (1) – cardboard packs.
50 ml – dark glass bottles (1) – cardboard packs.

Marketing Authorization Holder

Pharmtsentr Vilar JSC (Russia)

Dosage Form

Bottle OTC Icon Eucalimin Solution for topical application and inhalation 1%: 25 mL or 50 mL bottle

Dosage Form, Packaging, and Composition

Solution for topical application and inhalations 1% 1 L
Eucalimin (sum of phenolic compounds of Eucalyptus viminalis) 10 g

Excipients : ethanol.

25 ml – dark glass bottles (1) – cardboard packs.
50 ml – dark glass bottles (1) – cardboard packs.

TABLE OF CONTENTS